Anti-ceramide antibody and sphingosine-1-phosphate as potential biomarkers of unresectable non-small cell lung cancer.

IF 2.3 4区医学 Q3 ONCOLOGY

Pathology & Oncology Research Pub Date : 2025-01-06 eCollection Date: 2024-01-01 DOI:10.3389/pore.2024.1611929

Lilla Bűdi, Dániel Hammer, Rita Varga, Veronika Müller, Ádám Domonkos Tárnoki, Dávid László Tárnoki, Martina Mészáros, András Bikov, Péter Horváth

{"title":"Anti-ceramide antibody and sphingosine-1-phosphate as potential biomarkers of unresectable non-small cell lung cancer.","authors":"Lilla Bűdi, Dániel Hammer, Rita Varga, Veronika Müller, Ádám Domonkos Tárnoki, Dávid László Tárnoki, Martina Mészáros, András Bikov, Péter Horváth","doi":"10.3389/pore.2024.1611929","DOIUrl":null,"url":null,"abstract":"Objectives: Spingosine-1-phosphate (S1P) and ceramides are bioactive sphingolipids that influence cancer cell fate. Anti-ceramide antibodies might inhibit the effects of ceramide. The aim of this study was to assess the potential role of circulating S1P and anti-ceramide antibody as biomarkers in non-small cell lung cancer (NSCLC).Methods: We recruited 66 subjects (34 controls and 32 patients with NSCLC). Patient history and clinical variables were taken from all participants. Venous blood samples were collected to evaluate plasma biomarkers. If bronchoscopy was performed, bronchial washing fluid (BWF) was also analyzed. We measured the levels of S1P and anti-ceramide antibody with ELISA.Results: S1P levels were significantly higher in the NSCLC group (3770.99 ± 762.29 ng/mL vs. 366.53 ± 249.38 ng/mL, patients with NSCLC vs. controls, respectively, p < 0.001). Anti-ceramide antibody levels were significantly elevated in the NSCLC group (278.70 ± 19.26 ng/mL vs. 178.60 ± 18 ng/mL, patients with NSCLC vs. controls, respectively, p = 0.007). Age or BMI had no significant effect on anti-ceramide antibody or S1P levels. BWF samples had higher levels of anti-ceramide antibody (155.29 ± 27.58 ng/mL vs. 105.87 ± 9.99 ng/mL, patients with NSCLC vs. controls, respectively, p < 0.001). Overall survival (OS) was 13.36 months. OS was not affected by anti-ceramide antibody or S1P levels.Conclusion: Higher levels of S1P and anti-ceramide antibody were associated with active cancer. These results suggest that sphingolipid alterations might be important features of NSCLC.","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611929"},"PeriodicalIF":2.3000,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742942/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology & Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/pore.2024.1611929","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Spingosine-1-phosphate (S1P) and ceramides are bioactive sphingolipids that influence cancer cell fate. Anti-ceramide antibodies might inhibit the effects of ceramide. The aim of this study was to assess the potential role of circulating S1P and anti-ceramide antibody as biomarkers in non-small cell lung cancer (NSCLC).

Methods: We recruited 66 subjects (34 controls and 32 patients with NSCLC). Patient history and clinical variables were taken from all participants. Venous blood samples were collected to evaluate plasma biomarkers. If bronchoscopy was performed, bronchial washing fluid (BWF) was also analyzed. We measured the levels of S1P and anti-ceramide antibody with ELISA.

Results: S1P levels were significantly higher in the NSCLC group (3770.99 ± 762.29 ng/mL vs. 366.53 ± 249.38 ng/mL, patients with NSCLC vs. controls, respectively, p < 0.001). Anti-ceramide antibody levels were significantly elevated in the NSCLC group (278.70 ± 19.26 ng/mL vs. 178.60 ± 18 ng/mL, patients with NSCLC vs. controls, respectively, p = 0.007). Age or BMI had no significant effect on anti-ceramide antibody or S1P levels. BWF samples had higher levels of anti-ceramide antibody (155.29 ± 27.58 ng/mL vs. 105.87 ± 9.99 ng/mL, patients with NSCLC vs. controls, respectively, p < 0.001). Overall survival (OS) was 13.36 months. OS was not affected by anti-ceramide antibody or S1P levels.

Conclusion: Higher levels of S1P and anti-ceramide antibody were associated with active cancer. These results suggest that sphingolipid alterations might be important features of NSCLC.

查看原文本刊更多论文

抗神经酰胺抗体和鞘氨醇-1-磷酸作为不可切除的非小细胞肺癌的潜在生物标志物。

目的：spingosin -1-phosphate （S1P）和神经酰胺是影响癌细胞命运的生物活性鞘脂。抗神经酰胺抗体可能抑制神经酰胺的作用。本研究的目的是评估循环S1P和抗神经酰胺抗体作为生物标志物在非小细胞肺癌（NSCLC）中的潜在作用。方法：我们招募了66名受试者（34名对照组和32名非小细胞肺癌患者）。收集所有参与者的病史和临床变量。采集静脉血样本评估血浆生物标志物。如果进行支气管镜检查，也要分析支气管洗涤液（BWF）。ELISA法测定血清S1P和抗神经酰胺抗体水平。结果：NSCLC组S1P水平显著高于对照组（3770.99±762.29 ng/mL比366.53±249.38 ng/mL, p < 0.001）。抗神经酰胺抗体水平在NSCLC组显著升高（278.70±19.26 ng/mL vs. 178.60±18 ng/mL， NSCLC患者vs.对照组，p = 0.007）。年龄和BMI对抗神经酰胺抗体和S1P水平无显著影响。非小细胞肺癌患者与对照组相比，BWF样品的抗神经酰胺抗体水平更高（155.29±27.58 ng/mL vs 105.87±9.99 ng/mL, p < 0.001）。总生存期（OS） 13.36个月。抗神经酰胺抗体或S1P水平不影响OS。结论：高水平的S1P和抗神经酰胺抗体与活动性肿瘤相关。这些结果提示鞘脂改变可能是非小细胞肺癌的重要特征。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pathology & Oncology Research 医学-病理学

CiteScore

6.30

自引率

0.00%

发文量

134

审稿时长

4-8 weeks

期刊介绍： Pathology & Oncology Research (POR) is an interdisciplinary Journal at the interface of pathology and oncology including the preclinical and translational research, diagnostics and therapy. Furthermore, POR is an international forum for the rapid communication of reviews, original research, critical and topical reports with excellence and novelty. Published quarterly, POR is dedicated to keeping scientists informed of developments on the selected biomedical fields bridging the gap between basic research and clinical medicine. It is a special aim for POR to promote pathological and oncological publishing activity of colleagues in the Central and East European region. The journal will be of interest to pathologists, and a broad range of experimental and clinical oncologists, and related experts. POR is supported by an acknowledged international advisory board and the Arányi Fundation for modern pathology.